The dramatic rise in quark consumption is closely tied to broader shifts in consumer lifestyle and healthcare guidance. Alongside established fitness and athletic nutrition trends, market analysts point to the widespread adoption of GLP-1 weight-loss medications as a major catalyst. Because GLP-1 treatments suppress appetite while requiring patients to maintain elevated protein intake to prevent muscle loss, convenient, low-fat items like quark have become primary dietary recommendations.

Industry data indicates that high-protein dairy categories have expanded at double-digit rates over the past decade, with momentum accelerating significantly. Quark sales in Sweden jumped by 30% year-on-year, continuing an upward trajectory into 2026. Market metrics reveal that approximately 40% of Swedish households now regularly purchase quark, prompting regional competitors like Skånemejerier to report all-time high production runs as well.

To alleviate severe supply bottlenecks, Arla has committed a 450 million SEK capital investment to expand manufacturing infrastructure for quark and cottage cheese (keso) at its regional plants. However, dairy operations management—such as at Arla’s Linköping processing facility—acknowledges that retail orders continue to outpace available bottling and culturing lines, leaving the cooperative temporarily unable to meet full market demand.